H3 equine influenza a virus
AssigneeWisconsin Alumni Research Foundation
InventorsChristopher W. Olsen, Gabriele A. Landolt, Alexander I. Karasin
Life of this patent
Estimating the term…
Abstract
The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.
Claims34
1-4. (canceled)
An isolated recombinant vector comprising a nucleic acid segment for an influenza virus HA having SEQ ID NO:1 or a HA-1 portion thereof, or a HA having at least 90% amino acid sequence identity to SEQ ID NO:1 or a HA-1 portion thereof which does not encode a valine at position 78 or an asparagine at position 159.
An immunogenic composition comprising an isolated HA polypeptide having SEQ ID NO:1 or a HA-1 portion thereof, or a HA having at least 98% amino acid sequence identity to SEQ ID NO:1 or a HA-1 portion thereof which does not have a valine at position 78 or an asparagine at position 159.
- which does not have a valine at position 78 or an
22-25. (canceled)
A method to immunize a mammal against influenza, comprising administering to the mammal an effective amount of the recombinant vector of claim 5 or 41 or the immunogenic composition of claim 11 or 44.
A vaccine comprising the recombinant vector of claim 5 or 41 or an isolated HA polypeptide having SEQ ED NO:1 or a HA-1 portion thereof, a HA polypeptide having at least 98% amino acid sequence identity to SEQ ID NO:1 or a HA-1 portion thereof which does not have a valine at position 78 or an asparagine at position 159 in HA-1, or a HA polypeptide having at least 95% amino acid sequence identity to SEQ ID NO:1 or a HA-1 portion thereof which has an alanine at position 78 and a serine at position 159 in HA 1 in an amount effective to induce a prophylactic or therapeutic response against influenza infection.
29-43. (canceled)
(canceled)
A diagnostic method comprising:
- contacting a physiological sample of an animal suspected of containing anti-influenza virus antibodies with an isolated HA polypeptide having SEQ ID NO:1 or a HA-1 portion thereof, a HA polypeptide having at least 98% amino acid sequence identity to SEQ ID NO:1 or a HA-1 portion which does not have a valine at position 78 or an asparagine at position 159 in HA-1, or a HA polypeptide having at least 95% amino acid sequence identity to SEQ ID NO:1 or a HA-1 portion thereof, which has an alanine at position 78 and a serine at position 159 in HA-1;
- and determining whether the sample comprises antibodies specific for the isolated HA polypeptide.
39-40. (canceled)
An isolated recombinant vector comprising a nucleic acid segment for an influenza virus HA having at least 95% amino acid sequence identity to SEQ ID NO:1 or a HA-1 portion thereof, which has an alanine at position 78 and a serine at position 159 in HA-1.
An immunogenic composition comprising an isolated polypeptide having at least 95% amino acid sequence identity to SEQ ID NO:1 or a HA-1 portion thereof, which has an alanine at position 78 and a serine at position 159 in HA-1.
Dependencies are inferred from the claim text.